1Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke : the Framingham Study[J]. Stroke, 1991, 22(8): 983-8.
2Stewart S, Hart CL, Hole DJ, et al. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study[J]. Heart, 2001, 86(5): 516-21.
3Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Antieoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study [J]. J Am Med Assoc, 2001, 285(18): 2370-5.
4Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence [J]. Circulation, 2006, 114(2): 119-25.
5Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range[J]. Chest, 2001, 119(1 Suppl):8S-21S.
6Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation [J]. Circulation, 2007, 115(21): 2689-96.
7Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [J]. Circulation, 2006, 114(7): e257-354.
8Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and throm- boembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation[J]. Chest, 2010, 137(2): 263-72.
9Camm A J, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2010, 31 (19): 2369-2429.
10Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score[J]. J Am CoU Cardiol, 2011, 57(2): 173-80.
3Khecht S,Wihon SR, Haissaguene M. The 2010 update of the ESC guidelines for the maagemertt f atal fis- rillation[J]. Circulation, 2010, 74(12): 2534-7.
4Rieder M J, Riener AP, VKORC1 hap|otypes on warfarin dose [4. N Engl 93. Gage BF, et al. Effect of transcriptional regulation and J Med, 2005, 352(22): 2285-93.
